149 related articles for article (PubMed ID: 24735730)
1. One size does not fit all: can we choose the best sequence of treatment in asymptomatic castration-resistant prostate cancer patients?
Loriot Y; Massard C; Fizazi K
Eur Urol; 2014 Oct; 66(4):653-4. PubMed ID: 24735730
[No Abstract] [Full Text] [Related]
2. Re: Michael T. Schweizer, Xian C. Zhou, Hao Wang, et al. The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2014;66:646-52.
O'Cathail M; Sundar S
Eur Urol; 2015 Jun; 67(6):e113-e114. PubMed ID: 25534667
[No Abstract] [Full Text] [Related]
3. [Concomitant use of abiraterone acetate and triptorelin in patients with castration-resistant prostate cancer].
Rapoport LM; Bezrukov EA; Kondrashina AV
Urologiia; 2016 Feb; (1):58-61. PubMed ID: 28247705
[TBL] [Abstract][Full Text] [Related]
4. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
5. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
[TBL] [Abstract][Full Text] [Related]
6. [Study on the therapy of castration-resistant prostate cancer: randomized phase II study of abiraterone acetate plus LHRH therapy vs. abiraterone acetate without LHRH therapy in patients with progressive chemotherapy-naïve castration-resistant prostate cancer [SPARE - AP 67/11 of the Association of Urogenital Oncology (AUO)]].
Rexer H
Urologe A; 2014 Nov; 53(11):1665-7. PubMed ID: 25297491
[No Abstract] [Full Text] [Related]
7. Prostate cancer: Sequencing AR-targeted agents might be ineffective in mCRPC.
Heidenreich A; Pfister D
Nat Rev Urol; 2015 May; 12(5):246-7. PubMed ID: 25868561
[No Abstract] [Full Text] [Related]
8. Beyond approval: what is the most appropriate way to use the expanding Armamentarium in metastatic castration-resistant prostate cancer and how do we move forward?
Suzman D; Eisenberger M
Eur Urol; 2014 Nov; 66(5):826-8. PubMed ID: 24751214
[No Abstract] [Full Text] [Related]
9. Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
Conteduca V; Caffo O; Fratino L; Lo Re G; Basso U; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Zagonel V; Veccia A; Lolli C; Maines F; De Giorgi U
Future Oncol; 2015; 11(21):2881-91. PubMed ID: 26436290
[TBL] [Abstract][Full Text] [Related]
10. Response of prostate cancer to addition of dutasteride after progression on abiraterone.
Lian JP; Gao YY; Tang JJ; Chen X; Liu Y; Wu DL; Li ZF; Huang SS
Asian J Androl; 2021; 23(2):222-223. PubMed ID: 32896838
[No Abstract] [Full Text] [Related]
11. Making progress on progression in metastatic prostate cancer.
Armstrong AJ; Halabi S
J Clin Oncol; 2015 Apr; 33(12):1322-4. PubMed ID: 25667271
[No Abstract] [Full Text] [Related]
12. Metastatic prostate cancer in 2015: The new and the old that is new again.
Graff JN; Beer TM
Nat Rev Clin Oncol; 2016 Feb; 13(2):73-4. PubMed ID: 26718107
[No Abstract] [Full Text] [Related]
13. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
[TBL] [Abstract][Full Text] [Related]
14. The timing of radium-223 therapy in castration-resistant prostate cancer.
Sartor O
Clin Adv Hematol Oncol; 2015 Sep; 13(9):570-2. PubMed ID: 26452186
[No Abstract] [Full Text] [Related]
15. Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea.
Cho IC; Joung JY; Seo HK; Chung J; Park WS; Lee KH
J Cancer Res Ther; 2014; 10(2):251-7. PubMed ID: 25022374
[TBL] [Abstract][Full Text] [Related]
16. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
[TBL] [Abstract][Full Text] [Related]
17. The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
Teply BA; Luber B; Denmeade SR; Antonarakis ES
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):72-8. PubMed ID: 26857146
[TBL] [Abstract][Full Text] [Related]
18. Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.
Vogelzang NJ; Fizazi K; Burke JM; De Wit R; Bellmunt J; Hutson TE; Crane E; Berry WR; Doner K; Hainsworth JD; Wiechno PJ; Liu K; Waldman MF; Gandhi A; Barton D; Jungnelius U; Fandi A; Sternberg CN; Petrylak DP
Eur Urol; 2017 Feb; 71(2):168-171. PubMed ID: 27522164
[TBL] [Abstract][Full Text] [Related]
19. Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience.
Francini E; Fiaschi AI; Petrioli R; Laera L; Bianco V; Ponchietti R; Roviello G
Anticancer Drugs; 2015 Sep; 26(8):884-7. PubMed ID: 26053281
[TBL] [Abstract][Full Text] [Related]
20. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]